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Abstract: Ovarian cancer is one of the leading causes of cancer death for women throughout 
the Western world. Kaempferol, a natural flavonoid, has shown promise in the chemoprevention 
of ovarian cancer. A common concern about using dietary supplements for chemoprevention is 
their bioavailability. Nanoparticles have shown promise in increasing the bioavailability of some 
chemicals. Here we developed five different types of nanoparticles incorporating kaempferol 
and tested their efficacy in the inhibition of viability of cancerous and normal ovarian cells. 
We found that positively charged nanoparticle formulations did not lead to a significant reduc-
tion in cancer cell viability, whereas nonionic polymeric nanoparticles resulted in enhanced 
reduction of cancer cell viability. Among the nonionic polymeric nanoparticles, poly(ethylene 
oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) nanoparticles incorporat-
ing kaempferol led to significant reduction in cell viability of both cancerous and normal cells. 
Poly(DL-lactic acid-co-glycolic acid) (PLGA) nanoparticles incorporating kaempferol resulted 
in enhanced reduction of cancer cell viability together with no significant reduction in cell 
viability of normal cells compared with kaempferol alone. Therefore, both PEO-PPO-PEO and 
PLGA nanoparticle formulations were effective in reducing cancer cell viability, while PLGA 
nanoparticles incorporating kaempferol had selective toxicity against cancer cells and normal 
cells. A PLGA nanoparticle formulation could be advantageous in the prevention and treatment 
of ovarian cancers. On the other hand, PEO-PPO-PEO nanoparticles incorporating kaempferol 
were more effective inhibitors of cancer cells, but they also significantly reduced the viability 
of normal cells. PEO-PPO-PEO nanoparticles incorporating kaempferol may be suitable as a 
cancer-targeting strategy, which could limit the effects of the nanoparticles on normal cells while 
retaining their potency against cancer cells. We have identified two nanoparticle formulations 
incorporating kaempferol that may lead to breakthroughs in cancer treatment. Both PEO-PPO-
PEO and PLGA nanoparticle formulations had superior effects compared with kaempferol alone 
in reducing cancer cell viability.
Keywords: nanochemoprevention, kaempferol, ovarian cancer, nanoparticles, viability, natural 
compound
Introduction
Natural compounds with antioxidant properties that function to protect the human 
body against development of cancer1,2 are present in a variety of fruit and vegetables.3 
Natural dietary compounds have been reported to reduce the risk of development of 
diabetes,4 cardiovascular disease,5 prostate cancer,6 colorectal cancer,7 and ovarian 
cancer.8 Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) 
is a relatively common nontoxic, natural dietary compound which has been reported 
to reduce the risk of ovarian cancer.9 Kaempferol was found to inhibit estrogen 
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receptor alpha expression in breast cancer cells10 and to 
induce apoptosis in glioblastoma cells11 and lung cancer 
cells12 by activation of MEK-MAPK. Studies have shown 
that kaempferol also has anti-inflammatory effects via inhi-
bition of interleukin-413 and cyclo-oxygenase 2 expression 
by suppressing Src kinase14 and downregulating the NFκB 
pathway.15 Kaempferol is also effective in inhibiting angio-
genesis and inducing apoptosis in ovarian cancer cells.16–19 
In human studies, a significant 40% decrease in incidence 
of ovarian cancer was found for individuals with the highest 
quintile of kaempferol intake as compared with those in the 
lowest quintile.20 Despite promising preclinical results, the 
utility of such compounds for chemoprevention in humans 
has met with only limited success, largely due to inefficient 
systemic delivery and limited bioavailability of promising 
agents. Therefore, to achieve the maximum response to 
a chemopreventive agent, novel strategies are required to 
enhance the bioavailability of potentially useful agents and 
to reduce toxicity.
Nanotechnology is an emerging interdisciplinary field 
that encompasses biology, engineering, chemistry, and 
 medicine.21 Using nanotechnology for the development 
of efficient anticancer drug delivery systems is a recent 
advance in medical science.22–24 The ability of nanoparticles 
to incorporate entities renders them ideal carriers for various 
anticancer drugs.25,26 Because most anticancer drugs have 
poor solubility in water and low bioavailability, the use of 
nanocarriers enables cancer medications with low solubil-
ity in water to be prepared as solid or liquid formulations. 
 Nanoparticles comprised of biodegradable polymers have 
been studied for delivery of drugs.27,28 Significant advantages 
of using biodegradable polymers are their safety and the 
ability to control the time and rate of polymer degradation as 
well as timely release of the drug. Nanoparticles comprised of 
biodegradable polymers such as poly(lactic acid), poly(DL-
lactic acid-co-glycolic acid) (PLGA), poly(caprolactone), 
palmitic acid, and chitosan have been utilized for the delivery 
of anticancer drugs.27,28 In recent years, nanotechnology has 
been implemented and assessed in different areas of cancer 
therapeutics and management.29 Siddiqui et al reported 
that nanoencapsulated epigallocatechin-3-gallate retains 
its biological effectiveness, with over a 10-fold dose reduc-
tion advantage compared with nonencapsulated epigallocate-
chin-3-gallate when inhibiting cell growth, and proapoptotic 
and angiogenic effects.30
Ovarian cancer is one of the leading causes of cancer 
death in women throughout the Western world.31 There has 
been limited progress in the prevention, early diagnosis, 
and treatment of ovarian cancer to date,32,33 leaving this 
malignancy with an unchanged death rate over decades.31 
Chemoprevention of ovarian cancer using natural products 
has received more attention recently, and our earlier studies 
have indicated that kaempferol, a dietary flavonoid, is effec-
tive in inhibiting angiogenesis and inducing apoptosis in 
ovarian cancer cells.16–19 However, effective concentrations 
are often above 20–40 µM, which are not always physiologi-
cally attainable. In this study, five nanoparticle formulations 
of kaempferol were developed and their efficacy in inhibit-
ing the viability of malignant and normal ovarian cells was 
determined.
Materials and methods
Chemicals
Kaempferol (soluble, 50 mg/mL in dimethyl sulfoxide), poly-
ethylenimine (PEI, molecular weight 800 Da), PLGA (lactide 
to glycolide ratio 50:50, molecular weight 30–60 kDa), glycol 
chitosan, poly(amidoamine) (PAMAM) dendrimer (molecu-
lar weight 516), and polyvinyl alcohol (molecular weight 
31–50 kDa), tetrahydrofuran, ethanol, acetone, dimethyl 
sulfoxide, and Dulbecco’s phosphate-buffered saline solu-
tion were purchased from Sigma-Aldrich (St Louis, MO). 
Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene 
oxide) (PEO-PPO-PEO, Pluronic P123 surfactant) was 
obtained from BASF Corporation (Mount Olive, NJ). The 
chemical structures of kaempferol, PLGA, PEO-PPO-PEO, 
glycol chitosan or chitosan, PLGA-PEI, and PAMAM den-
drimer are shown in Figure 1. The PLGA-PEI polymer was 
synthesized using an aminolysis approach. In brief, PLGA 
was dissolved in tetrahydrofuran and PEI was dissolved in 
ethanol. The two solutions were then mixed at a PLGA to PEI 
mass ratio of 10:1 and stirred at 50°C for 30 minutes to form 
PLGA-PEI. The polymer solution was then dialyzed using a 
2 kDa dialysis membrane for 2 days and lyophilized.
Synthesis and characterization  
of nanoparticles incorporating kaempferol
The PEO-PPO-PEO, PLGA, PLGA-PEI, chitosan, and 
PAMAM nanoparticles were studied, and found to be biode-
gradable and to have good biocompatibility with normal cells 
and tissues. These five nanoparticles incorporated with and 
without kaempferol were synthesized using a nanoprecipita-
tion method.34 In brief, kaempferol was dissolved in dimethyl 
sulfoxide at a concentration of 0.2 M. PLGA, PAMAM, 
PEO-PPO-PEO, and PLGA-PEI were dissolved in acetone at 
a concentration of 20 g/L. Chitosan was dissolved in deion-
ized water at a concentration of 200 g/L and further mixed 
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with acetone to 20 g/L before synthesis of the nanoparticles. 
To synthesize the nanoparticles incorporating kaempferol, 
250 µL of kaempferol solution was mixed with 1 mL of 
polymer solution. Five mL of Dulbecco’s phosphate-buffered 
saline solution was added dropwise and gently stirred with 
a magnetic bar for 30 minutes. The solution was kept under 
ventilation for 6 hours and then gradually vacuumed until no 
vapor was observed. The resulting solution was concentrated 
at 2.5 mM under a speed vacuum concentrator (Thermo Fisher 
Scientific, Waltham, MA) or lyophilized as a powder; for 
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Figure 1 Chemical structures of kaempferol, PLgA, PEO-PPO-PEO, glycol chitosan, PLgA-PEI, and PAMAM dendrimer.
Abbreviations: PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PLgA, poly(DL-lactic acid-co-glycolic acid); PEI, polyethyleneimine; 
PAMAM, poly(amidoamine).
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lyophilized samples, Dulbecco’s phosphate-buffered saline 
solution was replaced with deionized water. To prepare 
the PLGA nanoparticles, polyvinyl alcohol was used as 
a surfactant and added in Dulbecco’s phosphate-buffered 
saline solution at a concentration of 0.5 wt%. Nanoparticles 
incorporating kaempferol were diluted and their size and 
surface potential were characterized using a 2000 Zetasizer 
(Malvern Instruments, Worcestershire, UK).
Cell culture
IOSE397 cells are normal ovarian surface epithelial cells 
immortalized with SV40 T/t, and were gifted for this research 
by Dr Nelly Auersperg, University of British Columbia, 
Canada. A2780/CP70 and OVCAR-3 ovarian cancer cell 
lines were from Dr Bing-Hua Jiang at Thomas Jefferson 
University, Philadelphia, PA. All cells were maintained in 
RPMI 1640 medium (Sigma-Aldrich) supplemented with 
10% fetal bovine serum (Life Technologies, Carlsbad, CA) 
at 37°C with 5% CO
2
.
Cell viability assay
Kaempferol alone, nanoparticles without kaempferol, kae-
mpferol mixed with but not incorporated into nanoparticles, 
and nanoparticles incorporating kaempferol were tested for 
their effects on the viability of malignant and/or normal 
ovarian cells. To test the effects of kaempferol alone and 
nanoparticles incorporating kaempferol, the cells were 
seeded in microplates at 8000 cells per well, incubated at 
37°C overnight, and treated with kaempferol or nanoparticles 
for 24 hours. Cell viability was analyzed using a CellTiter 
96 Aqueous one solution cell proliferation assay kit from 
Promega Corporation (Madison, WI). Optical density (OD) 
values were recorded at 490 nm.
Statistical analysis
The results were expressed as the mean ± standard error of the 
mean. During the screening process, optical density values 
were compared by t-test. For indepth analysis of selected 
nanoparticles, independent experiments were normalized 
and combined for statistical analysis. Statistical significance 
was set at P , 0.05.
Results and discussion
The synthesized PEO-PPO-PEO, PLGA, PLGA-PEI, chito-
san, and PAMAM nanoparticles were approximately 200 nm 
in size (Table 1). The PEO-PPO-PEO and PLGA nanopar-
ticles had almost no surface charge, while chitosan, PLGA-
PEI, and PAMAM nanoparticles had a positive surface 
charge, with PAMAM having the highest charge (Table 1).
We screened the five different types of kaempferol 
nanoparticles for their ability to inhibit viability of A2780/
CP70 cancer cells. As shown in Figure 2A–F, kaempferol in 
25 µM phosphate-buffered saline solution did not achieve 
any significant reduction in cell viability compared with 
unexposed controls. Neither nanoparticles plus kaempferol 
nor nanoparticles alone resulted in any significant change 
in A2780/CP70 cell viability compared with kaempferol in 
phosphate-buffered saline solution or the control. In contrast, 
PEO-PPO-PEO nanoparticles incorporating kaempferol 
achieved significant inhibition of A2780/CP70 cells and 
resulted in significant reduction in cell viability compared 
with kaempferol in phosphate-buffered saline solution (Fig-
ure 2A). PLGA nanoparticles incorporating kaempferol also 
showed marginally significant inhibitory effects compared 
with kaempferol in phosphate-buffered saline solution 
(P = 0.07, Figure 2B). The other three types of nanoparticle 
(ie, PLGA-PEI, chitosan, and PAMAM) did not achieve a 
significant reduction in A2780/CP70 cell viability compared 
with kaempferol in phosphate-buffered saline solution or the 
control, and no significant differences in ability to reduce 
cell viability were observed between these three nanoparticle 
types (Figure 2F).
These data suggest that nanoparticle chemistry plays an 
important role in the treatment of cancer if nanoparticles are 
used. Appropriate nanoparticle formulation or chemistry (ie, 
PEO-PPO-PEO) can lead to significant reduction of cancer 
cell viability (see Figure 1A). Positively charged nanopar-
ticles did not result in reduction of A2780/CP70 cell viability, 
while nonionic polymeric (eg, PEO-PPO-PEO) nanoparticles 
led to significant reduction in A2780/CP70 cell viability.
We also examined these chemicals in another ovar-
ian cancer cell line (ie, OVCAR-3). Consistent with the 
screening results for A2780/CP70 cells, PEO-PPO-PEO 
and PLGA nanoparticles incorporating kaempferol resulted 
in significantly lower OVCAR-3 cell viability compared 
with kaempferol in phosphate-buffered saline solution and 
the control (Figure 3). PLGA-PEI, chitosan, and PAMAM 
Table 1 Particle size and zeta potential of nanoparticles 
incorporating kaempferol (data are an average of three samples)
Nanoparticle Particle size (nm) Surface potential (mV)
PLgA 210 ± 40   +0.1 ± 3.4
PEO-PPO-PEO 160 ± 30   +1.4 ± 4.2
Chitosan 230 ± 70 +11.7 ± 5.9
PLgA-PEI 220 ± 50 +34.2 ± 7.9
PAMAM 250 ± 70 +37.2 ± 8.3
Abbreviations: PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly 
(ethylene oxide); PLgA, poly(DL-lactic acid-co-glycolic acid); PEI, polyethyleneimine; 
PAMAM, poly(amidoamine).
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nanoparticles resulted in higher cell viability compared 
with kaempferol in phosphate-buffered saline solution 
(Figure 3). Comparing  Figures 2F and 3, PEO-PPO-PEO 
and PLGA nanoparticles incorporating kaempferol led to 
lower viability of both A2780/CP70 and OVCAR-3 cancer 
cells than did kaempferol in phosphate-buffered saline 
solution, but the degree of reduction was significantly dif-
ferent. Moreover,  PEO-PPO-PEO and PLGA nanoparticles 
incorporating kaempferol showed greater activity against 
OVCAR-3 cells than A270/CP70 cells. This is consistent 
with the effect of kaempferol alone because kaempferol 
25 µM in phosphate-buffered saline solution significantly 
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Figure 2 Effects of nanoparticles incorporating kaempferol on A2780/CP70 ovarian cancer cells.
Notes: Ovarian cancer cells were seeded in a microplate, incubated overnight, and treated with 25 µM kaempferol for 24 hours. Cell viability was analyzed using an 
MTS-based method. *P , 0.05 as compared with kaempferol in phosphate-buffered saline solution and control.
Abbreviations: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NP, nanoparticle; OD, optical density; PEO-PPO-PEO, 
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PAMAM, poly(amidoamine); PBS, phosphate-buffered saline solution; PLgA, poly(DL-lactic acid-co-glycolic acid).
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Figure 3 Effects of nanoparticles incorporating kaempferol on OVCAR-3 ovarian cancer cells.
Notes: OVCAR-3 cells were seeded in a microplate, incubated overnight, and treated with 25 µM kaempferol for 24 hours. Cell viability was analyzed using an MTS-based 
method. **P , 0.01, *P , 0.05 versus control. #P , 0.01 versus kaempferol in phosphate-buffered saline solution.
Abbreviations: NP, nanoparticle; OD, optical density; PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PAMAM, poly(amidoamine); PBS, 
phosphate-buffered saline solution; PLgA, poly(DL-lactic acid-co-glycolic acid).
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Figure 4 Effects of PEO-PPO-PEO and PLgA nanoparticles incorporating 
kaempferol on OVCAR-3 ovarian cancer cells and immortalized IOSE397 epithelial 
ovarian cells at (A) 10 µM and (B) 25 µM. Ovarian cells were seeded in microplates, 
incubated overnight, and treated with kaempferol or its nanoparticles for 24 hours.
Notes: Viability of cells was measured using an MTS-based method. Data represent the 
mean ± standard error of the mean from a minimum of three independent experiments. 
*P , 0.05, **P , 0.01 versus kaempferol in phosphate-buffered saline solution. #P , 0.01 
versus PLgA nanoparticles incorporating kaempferol in treating the same cell type.
Abbreviations: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium; PBS, phosphate-buffered saline solution; NP, nanoparticle; 
PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PLgA, 
poly(DL-lactic acid-co-glycolic acid).
reduced the viability of OVCAR-3 cells (Figure 3) but not 
A2780/CP70 cells (Figure 2F). These  findings suggest that 
the treatment outcome depends on the type of cancer cell, 
and PEO-PPO-PEO and PLGA nanoparticles incorporating 
kaempferol could have potential application in different 
forms of ovarian cancer (even when kaempferol alone does 
not have a significant impact).
The effects of PEO-PPO-PEO and PLGA nanoparticles 
incorporating kaempferol were further compared with 
kaempferol in phosphate-buffered saline solution for their 
inhibitory effects on cancerous and normal ovarian cells 
at two different concentrations (10 µM and 25 µM). As 
shown in Figure 4, at 10 µM, PLGA nanoparticles incor-
porating kaempferol significantly reduced the viability of 
OVCAR-3 cells but had no significant influence on the 
viability of IOSE397 cells. This result was also found at 
the 25 µM concentration. However, PEO-PPO-PEO nano-
particles incorporating kaempferol significantly reduced the 
viability of both OVCAR-3 and IOSE397 cells compared 
with kaempferol in phosphate-buffered saline solution at 
concentrations of 10 µM and 25 µM. Overall, the higher 
the concentration (from 10 µM to 25 µM), the greater the 
reduction in OVCAR-3 cell viability. Moreover, it seemed 
that, at the same concentration, PEO-PPO-PEO nanopar-
ticles incorporating kaempferol were more effective in 
reducing OVCAR-3 cell viability compared with PLGA 
nanoparticles incorporating kaempferol, with a significant 
reduction seen at 10 µM (Figure 4A). PEO-PPO-PEO 
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Conclusion
Five nanoparticle formulations incorporating kaempferol 
were investigated for their potential in the treatment of ovarian 
cancer, and their efficacy was tested in vitro. Table 2 summa-
rizes the effects of PEO-PPO-PEO and PLGA nanoparticles 
incorporating kaempferol on cancerous and normal ovarian 
cells. In A2780/CP70 ovarian cancer cells, we found that 
nanoparticles incorporating kaempferol with positive charges 
(ie, PLGA-PEI, glycol chitosan, and PAMAM dendrimer) 
did not significantly reduce cell viability. PEO-PPO-PEO 
nanoparticles incorporating kaempferol significantly reduced 
cell viability compared with kaempferol alone, and PLGA 
nanoparticles incorporating kaempferol also showed notably 
enhanced reduction of the viability of A2780/CP70 cells. 
PEO-PPO-PEO and PLGA nanoparticles incorporating kae-
mpferol also significantly reduced the viability of OVCAR-3 
cancer cells, compared with kaempferol alone. These two 
kaempferol nanoparticles were further compared with 
kaempferol alone in immortalized IOSE397 ovarian cells 
and OVCAR-3 ovarian cancer cells. We found that PEO-
PPO-PEO nanoparticles incorporating kaempferol not only 
significantly reduced the viability of OVCAR-3 cancer cells 
but also that of normal IOSE397 cells compared with kaemp-
ferol alone. Interestingly, PLGA nanoparticles incorporating 
kaempferol significantly reduced the viability of OVCAR-3 
cancer cells but not normal IOSE397 cells compared with 
kaempferol alone. Therefore, the PLGA nanoparticle formu-
lation could be a promising candidate for cancer treatment 
due to its improved ability to reduce cancer cell viability 
along with no significant reduction in the viability of normal 
ovarian cells. PEO-PPO-PEO nanoparticles incorporating 
kaempferol were more effective in inhibiting the viability of 
cancer cells compared with PLGA nanoparticles incorporat-
ing kaempferol. If appropriately targeted, PEO-PPO-PEO 
nanoparticles incorporating kaempferol could be more effec-
tive in treating cancer. The mechanisms related to the effects 
of PEO-PPO-PEO and PLGA nanoparticles incorporating 
kaempferol on cancerous and normal ovarian cells are still 
unclear, so further investigation of these nanoparticles for bet-
ter nanochemoprevention of cancer is warranted.
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Table 2 Summary of the effects of PEO-PPO-PEO and PLgA 
nanoparticles incorporating kaempferol on cancerous and normal 
ovarian cells studied
Cell Kaempferol-PLGA  
NP
Kaempferol- 
PEO-PPO-PEO NP
Cancer cell
A2780/CP70 § ¶
OVCAR-3 ¶ ¶*
Normal cell
IOSE397 ** ¶^
Notes: ¶Significant reduction in viability compared with kaempferol in PBS; §notable 
reduction (P = 0.07) in viability compared with kaempferol in PBS; **no significant 
difference in viability compared with kaempferol in PBS; *significant reduction in 
viability at a low concentration (ie, 10 µM) but not at a high concentration (ie, 25 µM) 
compared with kaempferol-PLGA nanoparticles; ^significant reduction in viability 
versus kaempferol-PLgA nanoparticles.
Abbreviations: PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide); PLgA, poly(DL-lactic acid-co-glycolic acid); NP, nanoparticle; 
PBS, phosphate-buffered saline solution.
nanoparticles incorporating kaempferol also resulted in 
significant reduction of IOSE397 cell viability compared 
with PLGA nanoparticles incorporating kaempferol 
(Figure 4). These results suggest that incorporation of 
kaempferol into PEO-PPO-PEO and PLGA nanoparticles 
enhanced the effectiveness of kaempferol in reducing the 
viability of cancer cells, and PEO-PPO-PEO nanoparticles 
incorporating kaempferol were more effective than PLGA 
nanoparticles incorporating kaempferol. PLGA nanopar-
ticles incorporating kaempferol could discriminate between 
cancerous and normal cells, whereby the viability of cancer 
cells but not the normal cells was significantly affected by 
PLGA nanoparticles incorporating kaempferol compared 
with kaempferol alone.
It is worth mentioning that developing effective strat-
egies for targeting anticancer drugs or nanoparticles has 
also attracted attention.35–39 Sunoqrot et al recently reported 
a hybrid nanoparticle platform that may allow targeting 
kinetics to be effectively controlled through hybridization 
of targeted dendrimers using polymeric nanoparticles.39 
In their study, folate-targeted PAMAM dendrimers were 
incorporated into poly(ethylene glycol)-b-poly(D,L-
lactide) nanoparticles, and their combined passive and 
active targeting enabled precise control over the targeting 
kinetics of dendrimers to folate-overexpressing cells.39 
Similarly, folate-targeted kaempferol complexes could 
be incorporated into our PEO-PPO-PEO or PLGA nano-
particles to achieve high targeting efficacy against folate-
overexpressing cancerous cells while limiting potential 
effects on normal cells.
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